Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     
News

AFT’s Novatears on PBS

15/11/2018
Share:
Following the recent announcements that AFT Pharmaceuticals' NovaTears has been listed on the Pharmaceutical Benefits Scheme (PBS) the company will be promoting its newest dry eye treatment at RANCO Congress.

The lubricant and tear film stabiliser is designed to treat evaporative dry eye, and is free from preservatives, water and phosphates. It can be used for up to six months after opening.

According to AFT, the fact that NovaTears is water-free is a major benefit, as it means there is no microbial growth possible in the solution and allows for the delivery of preservative-free drops in a multi-dose bottle. NovaTears also has a droplet size 4–5x smaller than traditional water-based eye drops, which minimises spillover.

“NovaTears is a new class of dry eye therapy based on patented EyeSol technology, which can provide relief for EDE sufferers, and fulfill a significant patient need. It’s long-lasting and spreads very easily across the eye, providing relief without blurred vision, stinging or burning,” AFT CEO Dr Hartley Atkinson said. 

Watch video


Designs for Vision
advertisement





rectangle
advertisement
Editor's Suggestion
Hot Stories

rectangle
advertisement


OR
 

Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!